sglt2 inhibitors and glp 1 agonist Renal outcomes of GLP1 agonists in clinical practice Use of GLP-1 Receptor Agonists

But I think it was a bold and much needed policy move, she said

A head-to-head review of clinical studies determined that among available GLP-1 RAs, there were A1C reductions from 0.78% to 1.9%

Eulipidemic effects of berberine administered alone or in combination with other natural cholesterol-lowering agents

Health , vol

Thus, in perfect agreement with the recent ADA-EASD consensus report [6], we also encourage the adoption of GLP-1RA plus SGLT2i combination therapy in T2DM patients with established ASCVD (coronary artery disease, cerebrovascular disease, or peripheral arterial disease) or multiple risk factors for ASCVD (i.e., age 55 years, obesity, dyslipidemia, hypertension, current tobacco use, left ventricular hypertrophy, and/or proteinuria) whose HbA1c remains suboptimal despite initial treatment with only one of these agents

The authors declare that they have no conflicts of interest